KEMPHARM, INC 4
4 · KEMPHARM, INC · Filed Apr 21, 2015
Insider Transaction Report
Form 4
KEMPHARM, INCKMPH
Guenther Sven
Exec VP R&D
Transactions
- Conversion
Common Stock
2015-04-21+23,852→ 43,852 total - Conversion
Series C Convertible Preferred Stock
2015-04-21−136,410→ 0 total→ Common Stock (18,188 underlying) - Conversion
Series A Convertible Preferred Stock
2015-04-21−26,355→ 0 total→ Common Stock (3,514 underlying) - Conversion
Series B Convertible Preferred Stock
2015-04-21−16,129→ 0 total→ Common Stock (2,150 underlying)
Footnotes (2)
- [F1]The total represents shares received upon conversion of Series A, Series B and Series C convertible preferred stock.
- [F2]Effective upon the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C convertible preferred stock automatically converted into 0.13333 shares of common stock. The convertible preferred stock had no expiration date.